For 14 years International Alliances Limited (IAL), headed by P Reed Maurer, has conducted an annual survey to determine the most admired pharma companies in Japan. Each year, IAL evaluate 30 companies, 15 Japanese and 15 foreign affiliated firms. In 2012, says Mr Maurer it included the firms listed below:
Japanese: Asahi Kasei, Astellas, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Kissei, Kyorin, Kyowa Hakko Kirin, Mitsubishi Tanabe, Mochida, Otsuka, Santen, Shionogi, Takeda, Zeria.
Foreign: Abbott (from now own to be known as AbbVie), Alcon, AstraZeneca, Bayer, Bristol-Myers, Chugai (Roche-group), Eli Lilly, GlaxoSmithKline, Merck & Co (called MSD outside North America), Boehringer Ingelheim, Novartis, Novo Nordisk, Pfizer, Sanofi, UCB.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze